Results

Total Results: 275 records

Showing results for "end stage renal".

241. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/cad-women-diagnosis_research-protocol.pdf
     June 06, 2011 - contrast agent used during the procedure to visualize the coronary arteries may cause anaphylaxis or renal … Lesser increase in the left ventricular ejection fraction Increase in cardiac output by enhancing end-diastolic … KQ 4: Nephrogenic systemic fibrosis was added as an adverse event associated with late-stage chronic

242. Rapid Evidence Product_Nonemergent Percutaneous Coronary Intervention Versus Optimal Medical Treatment for Stable Ischemic Heart Disease: A Rapid Response Literature Review (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/rapid-evidence-heart-disease.pdf
     October 01, 2022 - EPC methods: AHRQ End-user perspectives of rapid reviews. Rockville (MD): 2016. … Fit for purpose: perspectives on rapid reviews from end-user interviews. … observational studies comparing at least two of these treatments in patients diagnosed with CAD and stage … Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. … observational studies comparing ≥2 treatments (PCI, CABG, or MT) in patients diagnosed with both CAD and stage

243. Adverse Events Associated With COVID-19 Pharmaceutical Treatments | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/COVID-19-pharmaceutical-treatments/rapid-research
     March 01, 2024 - Remdesivir in COVID-19 Patients with End Stage Renal Disease on Hemodialysis.

244. Distributed Ambulatory Research in Therapeutics Network (DARTNet): Summary Report | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/distributed-network-ambulatory-therapeutics/research
     January 01, 2019 - This report comes at the end of the initial development phase of DARTNet. … In these practices the paper form is given to patients at the end of a visit for educational and personal … Structure The DARTNet system is readily expandable, utilizing local parallel processing and a two stage … Other factors associated with adverse safety outcomes included renal dysfunction and certain specific … advent of new from on-going episodes of care, and track process and clinical outcomes within and at the end

245. Cystic-Fibrosis-Hgh Surveillance (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cystic-fibrosis-hgh_surveillance.pdf
     August 01, 2012 - Prevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survival. … deficiency: tumor in >80% of cases Not reported Retrospective cohort study Mean dose GH at the end … Among particular groups (e.g., Prader Willi syndrome, Turner Syndrome, renal insufficiency), deaths … hypertension:61 confirmed cases; most resolved with discontinuation of drug; increased risk in Chronic Renal … In one controlled trial, mean Tanner stage improved regardless of gender, and in an analysis of three

246. DARTNet Summary Report (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/distributed-network-ambulatory-therapeutics_research.pdf
     July 01, 2009 - This report comes at the end of the initial development phase of DARTNet. … Structure The DARTNet system is readily expandable, utilizing local parallel processing and a two stage … Other factors associated with adverse safety outcomes included renal dysfunction and certain specific … for the replication and propagation of DARTNet should CINA’s involvement with DARTNet come to an end … to protect University of Minnesota and to allow for DARTNet to continue should their involvement end

247. Rapid Evidence Product: Adverse Events Associated With COVID-19 Pharmaceutical Treatments (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/COVID-19-pharmaceutical-treatments-rapid-review.pdf
     March 01, 2024 - Remdesivir in COVID-19 Patients with End Stage Renal Disease on Hemodialysis. … Evidence-based Practice Center (EPC) Program is developing a range of rapid evidence products to assist end-users … RR = 0.34; CI: 0.01, 8.23 Wrist fracture: 0/1109, 1/1115 RR = 0.34; CI: 0.01, 8.23 Creatinine renal … Risk Factor Analysis Risk of Bias (ROB) Selvaraj, 202149 Remdesivir in COVID-19 patients with end … stage renal disease Letter to the editor Setting: Inpatient Cohort study N = 28 Population:

248. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/arthritis_hi_impact.pdf
     January 01, 2014 - noted that efficacy was demonstrated, they cited safety concerns about infection, cardiovascular, and renal … times greater than the general population, and the substantial mortality is due primarily to comorbid renal … Based on this input, our overall assessment is that this intervention is in the lower end of the … Committee form, EQ VAS quality of life score) were obtained from the base-line evaluation to the end … The results remained stable from the end of the therapy to 6 months followup, before significantly

249. Disparities-Quality-Improvement Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/disparities-quality-improvement_executive.pdf
     August 01, 2012 - ) – Hypertension • Cystic fibrosis • Depression (major depressive disorder only) • Diabetes • End-stage … renal disease • Pneumonia (including pneumococcal vaccination) • Pregnancy Studies had to include data … review; second, descriptions of the studies are organized by clinical condition as a reference for end

250. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/01_arthritis_potential_high_impact_2012-12-10.pdf
     January 01, 2012 - scores (IKDC form, EQ VAS quality of life score) were reported between the baseline evaluation, the end … Barr virus-associated posttransplant lymphoproliferative disorder was observed in patients who had renal

251. Rapid Response: Efficacy of Dental Services for Reducing Adverse Events in Those Receiving Chemotherapy for Cancer (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/rapid-response-chemotherapy-dental.pdf
     July 01, 2023 - oral or dental examination performed on an inpatient basis as part of comprehensive workup prior to renal … the body’s immune system, leading to impairment of resistance to infections and other disorders.7 Renal … reviewer was unsure regarding the appropriate disposition of a study (either at the abstract or full-text stage … Response, a thorough search of the MEDLINE database compiled all relevant published studies through the end … Evidence-based Practice Center (EPC) Program using streamlined literature review methods to assist end-users

252. Evidence-based Practice Center Future Research Needs (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/ongoing-studies-evidence_research.pdf
     December 01, 2010 - to suggest factors that might predict relevance and utility of the completed study and associated end-products … when compared to the trial registration, and only 45 percent of studies were registered before the end … While many of these registries are no longer in existence, they likely set the stage for current clinical … Additionally, the time frame 20 examined in this project is at an early stage when trial registration … Type II Diabetes and the Metabolic Syndrome and on Inflammatory Bowel Disease, Rheumatoid Arthritis, Renal

253. ADHD Medications and Risk of Serious Coronary Heart Disease in Yough and Middle-Aged Adults (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/adhd-heart-disease-children_research.pdf
     January 01, 2023 - other than non-melanoma skin cancer), HIV infection, organ transplant, liver failure or hepatic coma, end-stage … renal disease, respiratory failure, or severe congestive heart failure. … included to reduce the potential for misclassification and referred to the first 30 days after the end … The former use category began after indeterminate use ended (i.e., at 31 days after end of current use … of insurance coverage/pharmacy benefit, day before 65th birthday, or end of study period (December

254. Continuous-Outcomes-Quantitative-Synthesis Methods (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/continuous-outcomes-quantitative-synthesis_methods.pdf
     March 01, 2011 - The summary of final key points and recommendations are presented in Table 2 at the end of this chapter … The two end points of IQR and range are not symmetric around median (or mean) if the distribution of … Allowing for uncertainty due to missing data in meta- analysis--part 1: two-stage methods. … alter the conclusions of a meta-analysis with continuous outcomes: a case study of changes in renal … monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal

255. Disposition of Comments: Technical Brief 37 Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/tech-brief-37-opiod-use-adults-comments.pdf
     November 03, 2020 - factors associated with opioid use, and opioid-related harms and adverse outcomes are included at the end … Next Steps Several future areas of research are identified at the end of each section throughout the … assume long-term opioid use is automatically bad, and because policymakers do not always read to the end … I am now at Stage II Renal Failure. … of ersatz expected utility model you embrace- but you lack the honesty to state clearly what your end

256. 8 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-guidance-harms_methods.pdf
     November 01, 2008 - outcomes data, including data that showed no difference in gastrointestinal adverse events at the end … Development of instruments for assessing risk of bias specifically in studies of harms is still in an early stage … Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of

257. 8 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/methodsguide_chou_assessing_harms_when_comparing.pdf
     November 01, 2008 - outcomes data, including data that showed no difference in gastrointestinal adverse events at the end … Development of instruments for assessing risk of bias specifically in studies of harms is still in an early stage … Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of

258. Abnormal-Uterine-Bleeding Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/abnormal-uterine-bleeding_executive.pdf
     March 01, 2013 - • Who are healthy, and without renal impairment, hepatic impairment, intestinal disease, thyroid

259. Type-2-Diabetes-Medications-Update Surveillance (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/type-2-diabetes-medications-update_surveillance.pdf
     December 31, 2013 - pioglitazone at baseline (228 mg/dl), and for placebo plus pioglitazone at baseline (236 mg/dl) and end … No clinically significant changes in renal function. … Glimepiride(sulfo nylureas) with metformin RCT 68 normoalbuminuric type 2 diabetes patients 1 year Renal … A total of 39.2 (exenatide) vs. 20.8% (insulin) of patients reached the composite end point of A1C … Yale, 201345 Canagliflozin Placebo RCT 269 subjects with type 2 diabetes and stage 3 chronic kidney

260. Assessing Harms when Comparing Medical Interventions | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/methods-guidance-harms/methods
     May 01, 2020 - the outcomes data, including data that showed no difference in gastrointestinal adverse events at the end … Development of instruments for assessing risk of bias specifically in studies of harms is still in an early stage … Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized